Correspondingly, the treatment of GLP-1 RAs for one week in rats with type 2 diabetes could reduce NOX3 and SOD2 levels in the retina cells, alleviate autophagy through the GLP-1R-ERK1/2-HDAC6 signaling pathway, and finally improve DR [34]
Secondary outcomes included diagnoses of depression, mood disorder, insomnia, broadly defined cognitive deficits, nerve disorders, peripheral neuropathy, and substance-related disorders
These trials received funding from the medication manufacturers, which means theres a potential for bias and conflict of interest
Cardiologists recommended combined therapy for patients with established cardiovascular disease or high cardiovascular risk who were already on treatment with one of the two drugs and had an HbA1c above target
If nausea is a concern, glycine may be prioritized